GlassScriptPhysician profile
Swaroopa Pulivarthi
NPI 1780174268
$2,879.70
in general payments reported to CMS, 2019-2025
22 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $138 · 2024: $1,030 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.18 | 2023-2025 | |
| Ucb, INC. | $446.79 | 2023-2025 | Fintepla, Rystiggo, Briviact |
| Pfizer INC. | $279.49 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $189.46 | 2024-2025 | Ultomiris |
| Argenx US, INC. | $159.79 | 2025 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $158.43 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.55 | 2022-2025 | Gammagard, Hyqvia |
| Eisai INC. | $144.16 | 2024-2025 | |
| Horizon Therapeutics Plc | $124.40 | 2022 | |
| Neurocrine Biosciences, INC. | $117.72 | 2024 | Ingrezza |
| Livanova USA, INC. | $100.04 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Axsome Therapeutics, INC. | $81.65 | 2025 | Symbravo |
| Lilly USA, LLC | $78.80 | 2025 | Kisunla, Amyvid |
| Jazz Pharmaceuticals INC. | $69.41 | 2022-2023 | Epidiolex |
| Genentech USA, INC. | $58.74 | 2025 | Ocrevus Zunovo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.08 | 2025 | Austedo Xr |
| Tersera Therapeutics LLC | $35.16 | 2024 | Quzyttir |
| Novartis Pharmaceuticals Corporation | $32.61 | 2023-2025 | |
| Grifols USA, LLC | $30.00 | 2025 | Gamunex-C |
| Aucta Pharmaceuticals, INC. | $28.31 | 2024 | Motpoly Xr |
| Amneal Pharmaceuticals LLC | $18.70 | 2025 | Crexont |
| Tanabe Pharma America, INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swaroopa Pulivarthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.